



RCSI



INTRODUCING NEW STAFF MEMBERS: Prof. Paul Murray

Name /RCSI appointment	We are pleased to welcome Paul Murray to RCSI Bahrain as Professor of Pathology and Head of the Department of Pathology.
Educational background (50 words)	Paul began his career in clinical laboratory medicine before obtaining Masters and PhD degrees working in Lawrence Young's lab' at the University of Birmingham where he began to study how the Epstein-Barr virus (EBV) contributes to the pathogenesis of Hodgkin lymphoma and other EBV-associated malignancies.
Summary of Career to date. (Max 100 words)	He was awarded a prestigious Louise Buchanan Fulbright Fellowship to continue his work on EBV in the Ambinder lab' at the Johns Hopkins University before setting up his own laboratory in the University of Birmingham. He was subsequently appointed Professor of Molecular Pathology in the University of Birmingham and held Cancer Research UK and Leukaemia Research Fund Programme grants as well numerous project grants, including Medical Research Council awards. More recently, he has also worked at the University of Limerick establishing the Limerick Cancer Research Centre as its founding director. He has >200 papers with an H-index of 68.
Research interests and specialty (List up to 8)	<ol style="list-style-type: none">1. Epstein-Barr virus and cancer2. Tumour microenvironments3. Hodgkin lymphoma4. Diffuse large B cell lymphoma5. Other viral driven malignancies6. Spatial tissue proteomics
Major accomplishments (100 words max)	Paul's work has contributed important discoveries in the field, including: the first description of the c-FLIP-mediated anti-apoptotic phenotype in lymphoma (Dutton et al., PNAS 2003); the discovery of aberrant mTOR kinase activation in Hodgkin lymphoma leading to clinical trials of mTOR inhibitors (Dutton et al., J Pathol 2005); oncogenic lipids as a novel target of EBV infection in tumours (e.g. Baumforth et al., Blood; 2005, Vrzalikova et al., Leukemia, 2018; Lupino et al, Leukemia 2019); and the identification of collagen receptor signalling as a mediator of chemotherapy resistance (Cader et al., Blood 2013).